miRview® mets2 home
- About the disease
- About the test
- Why do I need this test?
- How will I benefit?
- How can I be tested?
- About us
- miRview® home
KNOW, THEN TREAT
miRview® mets2 is cutting-edge molecular diagnostic test that leverages microRNA
to accurately identify the tissue-of-origin of tumors, helping you make informed decisions.
The overall prognosis in patients with CUP is poor1. They often undergo a wide range of costly, time-consuming, and inefficient tests in an attempt to identify the primary site of origin2. Unfortunately, many of the diagnostic tests currently in use are inadequate2.
miRview® mets2 accurately identifies the tissue-of-origin of tumors
Until now, there has been an unmet need for accurate and time-efficient testing to determine primary origin2. miRview® mets2 is a microRNA-based molecular diagnostic test that identifies the tissue-of-origin of metastatic tumors in both CUP patients and those who are not yet diagnosed. The test offers:
miRview® mets2 delivers quality resultsThe miRview® mets2 assay uses quantitative technology to determine the expression of microRNA in tumor tissue. In the majority of cases, the miRview® mets2 assay returns a single tissue prediction with 90% sensitivity and 99% specificity3.
The miRview® mets2 assay is easy to usemiRview® mets2 is based on formalin-fixed paraffin-embedded (FFPE) tumor samples, the current standard for preserving tumors in the post-op setting. FFPE samples require minimal preparation to be analyzed by our experts and can be easily shipped via any air courier.